http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Parenteral, non-live rotavirus vaccine: recent history and future perspective
송재민 대한백신학회 2021 Clinical and Experimental Vaccine Research Vol.10 No.3
Since the widespread introduction of oral and live attenuated rotavirus vaccines around the world in 2009, the impacts of disease burden and the effects of disease reduction in developing countries have been proven. However, in low and middle-income countries, the vaccine efficacy is somewhat lower than in developed countries due to differences in nutritional conditions, microbial environments of individuals, and other factors. In addition, as oral, live vaccines have been found to be associated with rare but serious side effects, the development of a next-generation vaccine with safety, improved effectiveness, and ease of storage is currently underway. New vaccine strain developed by the Centers for Disease Control and Prevention in the United States are undergoing preclinical testing of efficacy, antigen dose, and administration route in the form of a heat-treated inactive vaccine, and a recombinant protein-based trivalent subunit vaccine developed by the Program for Appropriate Technology in Health is undergoing clinical trial in phase III. Several research groups are also developing non-replicating protein-based rotavirus vaccines using virus-like particles and nanoparticles. This review provides a brief overview of the development status and technology of parenteral, non-live rotavirus vaccines worldwide.
Won, G.,Kim, B.,Lee, J.H. Elsevier Ltd. 2017 Vaccine Vol.35 No.25
Salmonella enterica serovar Typhi ghost was constructed as a vaccine candidate against typhoid fever. An asd<SUP>+</SUP> plasmid pJHL187 harboring a ghost cassette comprised of PhiX 174 E lysis gene stringently controlled under the convergent promotor components and was transformed into the asd gene-deleted mutant S. Typhi Ty21a strain (STG). Twenty female BALB/c mice randomly assigned into two groups were subcutaneously vaccinated at 5weeks of age to assess immunogenic characteristics of the constructed STG. The level of serum IgG in the immunized mice was significantly increased during the observational period (P<0.001) as the mice showed the significant elevation of secretory IgA at week 6 compared to those in the non-immunized mice (P<0.05). The CD3<SUP>+</SUP>CD4<SUP>+</SUP> T cell subpopulation in the primed splenocytes showed approximately twofold increase in the immunized group. Further, the gene expression of various immunomodulatory cytokines associated with Th-1, Th-2 and Th-17 immunity was observed in in vitro restimulated splenocytes isolated from the immunized mice. Serum Bactericidal activity of antibodies produced in the rabbits immunized with STG was proved by the elimination of almost all of wild-type S. Typhi in the presence of exogenous complement over an hour at week 6 after the first immunization. The immuno-stimulatory traits of STG demonstrated that the construct effectively enhanced the immunological responses, providing a potential of STG as the vaccine candidate against typhoid fever.